Deleterious GRM1 mutations in schizophrenia

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ayoub, Mohammed Akli ^a   Angelicheva, Dora ^a   Vile, David ^b   Chandler, David ^a   Morar, Bharti ^a   Cavanaugh, Juleen A ^c   Visscher, Peter M ^d   Jablensky, Assen ^b,e   Pfleger, Kevin D G ^a   Kalaydjieva, Luba ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL PHOSPHATE; METABOTROPIC RECEPTOR 1; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; SCHIZOPHRENIA; SEGREGATION ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CASE CONTROL STUDY; CELL STRAIN COS1; CERCOPITHECUS; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION; GENETICS; MUTATION; PEDIGREE; PHENOTYPE;

ANIMALIA;

ANIMALS; CASE-CONTROL STUDIES; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; PEDIGREE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84858651719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032849     Document Type: Article

References (58)

1. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, et al. (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407: 971-977.
2. Shigemoto R, Nakanishi S, Mizuno N, (1992) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 322: 121-135.
3. Martin LJ, Blackstone CD, Huganir RL, Price DL, (1992) Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9: 259-270.
4. Simonyi A, Ngomba RT, Storto M, Catania MV, Miller LA, et al. (2005) Expression of groups I and II metabotropic glutamate receptors in the rat brain during aging. Brain Res 1043: 95-106.
5. Lavreysen H, Nóbrega Pereira S, Leysen JE, Langlois X, Lesage ASJ, (2004) Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology 46: 609-619.
6. Lesage A, Steckler T, (2010) Metabotropic glutamate mGlu1 receptor stimulation and blockade: Therapeutic opportunities in psychiatric illness. Eur J Pharmacol 639: 2-16.
7. Heidinger V, Manzerra P, Wang ZQ, Strasser U, Yu S-P, et al. (2002) Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 22: 5452-5461.
8. Lindemeyer K, Leemhuis J, Löffler S, Grass N, Nörenberg W, et al. (2006) Metabotropic glutamate receptors modulate the NMDA- and AMPA-induced gene expression in neocortical interneurons. Cereb Cortex 16: 1662-1677.
9. Benquet P, Gee CE, Gerber U, (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22: 9679-9686.
10. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, et al. (1994) Reduced hippocampal log-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 79: 365-375.
11. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, et al. (1994) Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 372: 237-243.
12. Gil-Sanz C, Delgado-Gracia JM, Fairen A, Gruart A, (2008) Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cereb Cortex 18: 1653-1663.
13. Neyman S, Manahan-Vaughan D, (2008) Metabotropic glutamate receptor 1 (mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in the hippocampal CA1 region in vitro. Eur J Neurosci 27: 1345-1352.
14. Merlin LR, Bergold PJ, Wong RK, (1998) Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J Neurophysiol 80: 989-993.
15. Huber KM, Kayser MS, Bear MF, (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent LTD. Science 288: 1254-1257.
16. Raymond CR, Thompson VL, Tate WP, Abraham WC, (2000) Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci 20: 969-976.
17. Bassell GJ, Warren ST, (2008) Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214.
18. Ronesi JA, Huber KM, (2008) Metabotropic glutamate receptors and fragile X mental retardation protein: partners in translational regulation at the synapse. Sci Signal 1 (5): pe6.
19. Krystal JH, Karper LP, Seibyl JP, Freeeman GK, Delaney R, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
20. Olney JW, Farber NB, (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
21. Moghaddam B, Adams B, Verma A, Daly D, (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
22. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, et al. (2011) Glutamate in schizophrenia: a focused review and meta-analysis of H-MRS studies. Schizophrenia Bull epub ahead of print 2011 July 11; PubMed PMID: 21746807.
23. Carter CJ, (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86: 1-14.
24. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, et al. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57: 123-131.
25. Volk DW, Eggan SM, Lewis DA, (2010) Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 167: 1489-1498.
26. Brody SA, Conquet F, Geyer MA, (2003) Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci 18: 2261-3366.
27. Frank RA, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P, et al. (2011) Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS One 6: e19011.
28. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al. (1990) SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47: 589-593.
29. Castle DJ, Jablensky A, McGrath JJ, Carr V, Morgan V, et al. (2006) The diagnostic interview for psychoses (DIP): development, reliability and applications. Psychol Med 36: 69-80.
30. Hallmayer JF, Kalaydjieva L, Badcock J, Dragovic M, Howell S, et al. (2005) Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 77: 468-476.
31. Woodbury MA, Clive J, Garson A Jr, (1978) Mathematical typology: a grade of membership technique for obtaining disease definition. Comput Biomed Res 11: 277-298.
32. Manton KG, Korten A, Woodbury MA, Anker M, Jablensky A, (1994) Symptom profiles of psychiatric disorders based on graded disease classes: an illustration using data from the WHO International Pilot Study of Schizophrenia. Psychol Med 24: 133-144.
33. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
34. Ng PC, Henikoff S, (2001) Predicting deleterious amino acid substitutions. Genome Res 11: 863-874.
35. Ferrer-Costa C, Orozco M, de la Cruz X, (2004) Sequence-based prediction of pathological mutations. Proteins 57: 811-819.
36. Capriotti E, Calabrese R, Casadio R, (2006) Predicting the insurgence of human genetic diseases associated to single point mutations with support vector machines and evolutionary information. Bioinformatics 22: 2729-2734.
37. Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, et al. (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucl Acids Res 37: e67.
38. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR, (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucl Acids Res 31: 3568-3571.
39. Enz R, (2006) The trick of the tail: protein-protein interactions of metabotropic glutamate receptors. Bioessays 29: 60-73.
40. Girard SL, Gauthier J, Noreau A, Xiang L, Zhou S, et al. (2011) Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet 43: 860-863.
41. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, et al. (2011) Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet 43: 864-868.
42. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, et al. (2010) Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet 87: 316-324.
43. Karchin R, (2009) Next generation tools for the annotation of human SNPs. Brief Bioinform 10: 35-52.
44. Sato T, Shimada Y, Nagasawa N, Nakanishi S, Jingami H, (2003) Amino acid mutagenesis of the ligand binding site and the dimmer interface of the metabotropic glutamate receptor 1. J Biol Chem 278: 4314-4321.
45. Rovati GE, Capra V, Neubig RR, (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959-964.
46. O'Connor V, El Far O, Bofill-Cardona E, Nanoff C, Freissmuth M, et al. (1999) Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling. Science 286: 1180-1184.
47. Kenakin T, (2009) How different tissues process drug response. In: Kenakin T, editors. A Pharmacology Primer: theory, applications and methods, 3rd Edition Burlington Elsevier Academic Press pp. 21-41.
48. Dalrymple MB, Pfleger KD, Eidne KA, (2008) G protein-coupled receptor dimers: Functional consequences, disease states and drug targets. Pharmacol Ther 118: 359-371.
49. Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, et al. (2008) A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 82: 160-164.
50. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, et al. (2009) Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 18: 988-996.
51. Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, et al. (2010) Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet 153B: 937-947.
52. Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, et al. (2008) Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 82: 150-159.
53. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Viiet WA, et al. (2008) CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry 13: 261-266.
54. Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
55. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, et al. (2009) Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet 46: 511-523.
56. Paul IA, Skolnik P, (2003) Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 1003: 250-272.
57. Grueter BA, McElligott ZA, Winder DG, (2007) Group I mGluRs and long-term depression: potential roles in addiction? Mol Neurobiol 36: 232-244.
58. Ribeiro FM, Paquet M, Cregan SP, Ferguson SSG, (2010) Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets 9: 574-595.